@Article{or.2024.045564,
AUTHOR = {YONGJIAN HUANG, JINZHOU WANG, JIUHUA XU, NING RUAN},
TITLE = {Remodeling tumor microenvironment using pH-sensitive biomimetic co-delivery of TRAIL/R848 liposomes against colorectal cancer},
JOURNAL = {Oncology Research},
VOLUME = {32},
YEAR = {2024},
NUMBER = {11},
PAGES = {1765--1776},
URL = {http://www.techscience.com/or/v32n11/58376},
ISSN = {1555-3906},
ABSTRACT = { <b>Background:</b> Despite significant advancements in the development of anticancer therapies over the past few decades, the clinical management of colorectal cancer remains a challenging task. This study aims to investigate the inhibitory effects of cancer-targeting liposomes against colorectal cancer. <b>Materials and Methods:</b> Liposomes consisting of 3β-[N-(N′, N′-dimethylamino ethane)carbamoyl]-cholesterol (DC-CHOL), cholesterol (CHOL), and dioleoylphosphatidylethanolamine (DOPE) at a molar ratio of 1:1:0.5 were created and used as carriers to deliver an apoptosis-inducing plasmid encoding the tumor necrosis factor-related apoptosis-inducing ligand (pTRAIL) gene, along with the toll-like receptor (TLR7) agonist Rsiquimod (R848). The rationale behind this design is that pTRAIL can trigger cancer cell apoptosis by activating the DR4/5 receptor, while R848 can stimulate the immune microenvironment. <b>Results:</b> Experimental results demonstrated the synergistic effects of R848 and pTRAIL encapsulated by liposomes (RTL) in suppressing the proliferation of colorectal cancer cells. Moreover, further <i>in vivo</i> investigations revealed the strong anti-tumor efficacy of RTL in xenograft and orthotropic <i>in situ</i> models of colorectal cancer. <b>Conclusions:</b> These findings collectively highlight the therapeutic potential of R848/pTRAIL-loaded liposomes in the treatment of colorectal cancer.},
DOI = {10.32604/or.2024.045564}
}